Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Critical Tariff-Related M&A Due Diligence Questions

    Recent tariff-related disruptions have significantly expanded the scope of M&A due diligence, with buyers now asking target companies an array of questions to assess new trade policy risk.

    Read more
  • Inflexion Raises a Multi-Asset Continuation Fund for Four Assets

    William Blair acted as a financial advisor to Inflexion Buyout V Investments LP, in connection with the successful close of a £2.3 billion multi-asset continuation fund, the Inflexion Continuation Fund I.

    Read more
  • College Was Awesome. Now What?

    College graduation marks the start of a career with new responsibilities and decisions. It can be an exciting time but filled with uncertainty.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures